期刊
ACTA BIOMATERIALIA
卷 132, 期 -, 页码 37-51出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2021.03.002
关键词
Organoid; Disease modeling; Microfluidics; Biomaterials; Personalized medicine; Drug screening
资金
- Ministry of Food and Drug Safety (MFDS), Repub-lic of Korea [19172MFDS168]
- National Research Foundation of Korea (NRF) - Ministry of Science and ICT (MSIT) , Re-public of Korea [2018M3A9H1021382]
Advancements in organoid technology have allowed for better replication of in vivo organ environments, overcoming limitations of existing disease models. Integration of engineering approaches such as microfluidics and biomaterials is necessary for more precise disease modeling. Combined with organoids, these engineered disease models provide a powerful platform for personalized medicine research.
As life expectancy improves and the number of people suffering from various diseases increases, the need for developing effective personalized disease models is rapidly rising . The development of organoid technology has led to better recapitulation of the in vivo environment of organs, and can overcome the constraints of existing disease models. However, for more precise disease modeling, engineering approaches such as microfluidics and biomaterials, that aid in mimicking human physiology, need to be integrated with the organoid models. In this review, we introduce key elements for disease modeling and recent engineering advances using both liver and lung organoids. Due to the importance of personalized medicine, we also emphasize patient-derived cancer organoid models and their engineering approaches. These organoid-based disease models combined with microfluidics, biomaterials, and co-culture systems will provide a powerful research platform for understanding disease mechanisms and developing precision medicine; enabling preclinical drug screening and drug development. Statement of significance The development of organoid technology has led to better recapitulation of the in vivo environment of organs, and can overcome the constraints of existing disease models. However, for more precise disease modeling, engineering approaches such as microfluidics and biomaterials, that aid in mimicking human physiology, need to be integrated with the organoid models. In this review, we introduce liver, lung, and cancer organoids integrated with various engineering approaches as a novel platform for personalized disease modeling. These engineered organoid-based disease models will provide a powerful research platform for understanding disease mechanisms and developing precision medicine. (c) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据